利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.022 秒)

    COLONOSCOPY - PREPARATION
    1.
    发明申请
    COLONOSCOPY - PREPARATION 有权

    公开(公告)号：US20210000866A1

    公开(公告)日：2021-01-07

    申请号：US17025531

    申请日：2020-09-18

    申请人： NORGINE BV

    发明人： Marc HALPHEN ,  Hans-Jurgen GRUSS ,  Ian COX ,  Alasdair COCKETT ,  Peter STEIN ,  Alex UNGAR

    IPC分类号： A61K33/14 ,  A61K9/00 ,  A61K31/375 ,  A61K47/02 ,  A61K47/22 ,  A61K9/08 ,  A61K31/77 ,  A61K31/765 ,  A61K33/04

    摘要： The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and h) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval—administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.

    Colonoscopy-preparation
    2.
    发明授权
    Colonoscopy-preparation 有权

    公开(公告)号：US10780112B2

    公开(公告)日：2020-09-22

    申请号：US16788590

    申请日：2020-02-12

    申请人： NORGINE BV

    发明人： Marc Halphen ,  Hans-Jurgen Gruss ,  Ian Cox ,  Alasdair Cockett ,  Peter Stein ,  Alex Ungar

    IPC分类号： A61K33/14 ,  A61K33/04 ,  A61K31/375 ,  A61K31/77 ,  A61K31/765 ,  A61K9/08 ,  A61K47/02 ,  A61K47/22 ,  A61K9/00

    摘要： The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval —administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.

    SOLID PREPARATION
    5.
    发明申请
    SOLID PREPARATION 审中-公开
    固体制剂

    公开(公告)号：US20140178477A1

    公开(公告)日：2014-06-26

    申请号：US14190528

    申请日：2014-02-26

    申请人： Norgine BV

    发明人： Tomohiro Yoshinari ,  Yutaka Ebisawa ,  Hiroshi Suzuki

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/536

    CPC分类号： A61K9/2095 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/536

    摘要： The present invention provides a solid preparation formulation containing a poorly water-soluble agent having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, in which the saccharide/cellulose weight ratio exceeds 2 and the cellulose content is not less than 5 wt %. This formulation provides a composition that can be produced with direct granulation, yet which delivers stability during production and storage.

    摘要翻译： 本发明提供了含有低熔点的水难溶性试剂，糖类和选自结晶纤维素和低取代羟丙基纤维素的纤维素的固体制剂制剂，其中糖/纤维素重量比超过2，和 纤维素含量不小于5重量％。 该制剂提供了可以用直接造粒制备的组合物，但是其在生产和储存期间提供稳定性。

    PROGNOSTIC METHOD
    6.
    发明申请
    PROGNOSTIC METHOD 失效
    预处理方法

    公开(公告)号：US20130042671A1

    公开(公告)日：2013-02-21

    申请号：US13660912

    申请日：2012-10-25

    申请人： NORGINE BV

    发明人： Hans-Jürgen Gruss ,  Ronald Oude Elferink ,  Dirk De Waart ,  Bruno Stieger

    IPC分类号： G01N33/49

    CPC分类号： G01N33/5005 ,  G01N33/582 ,  G01N33/6872 ,  Y10T436/173845 ,  Y10T436/18 ,  Y10T436/201666 ,  Y10T436/203332

    摘要： A method of determining the functional activity of the MRP2 and/or MRP3 efflux pathway of a human or animal subject was disclosed. The method comprises (i) determining the level of a bile acid derivative in the blood of said human or animal subject at a predetermined time interval after introducing an amount of the bile acid derivative into the subject, and (ii) using the determination obtained in step (i) to indicate the functional activity of the MRP2 and/or MRP3 efflux pathway of the subject.

    摘要翻译： 公开了确定人或动物受试者的MRP2和/或MRP3流出途径的功能活性的方法。 该方法包括（i）在将一定量的胆汁酸衍生物引入受试者之后，以预定的时间间隔确定所述人或动物受试者的血液中胆汁酸衍生物的水平，和（ii）使用 步骤（i）以指示受试者的MRP2和/或MRP3流出途径的功能活性。

    Solutions comprising polyethylene glycol and electrolytes
    10.
    发明授权
    Solutions comprising polyethylene glycol and electrolytes 有权
    包含聚乙二醇和电解质的溶液

    公开(公告)号：US09468686B2

    公开(公告)日：2016-10-18

    申请号：US14166716

    申请日：2014-01-28

    申请人： NORGINE BV

    发明人： Chris Seldon ,  Dawn Padfield ,  Frances Morrissey

    IPC分类号： A61K47/14 ,  A61K31/08 ,  A61K47/10 ,  A61K33/14 ,  A61K9/00

    CPC分类号： A61K47/14 ,  A61K9/0095 ,  A61K31/08 ,  A61K31/77 ,  A61K33/14 ,  A61K47/10

    摘要： A solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N x an amount of flavouring; and (g) optionally N×an amount of sweetener, where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.

    摘要翻译： 在水中的溶液，其含有以下浓度的以下组分：（a）平均分子量为2500至4500的N×（70至130）g / L聚乙二醇（PEG）; （b）N×（1.6〜4.0）g / L氯化钠; （c）N×（0.2〜0.6）g​​ / L氯化钾; （d）N×（0.6〜2.2）g / L碳酸氢钠; （e）N×防腐剂量; （f）任选地N x一定量的调味剂; 和（g）任选的N×一种甜味剂的量，其中N在2至8的范围内。该溶液是用于稀释的浓缩物。 在使用中，用水稀释N倍，以提供用于治疗便秘或粪便冲击的受试者的溶液。 还提供了包括或使用溶液的溶液，试剂盒，单位剂量和方法。